Clinical Trials
68 trialsNCT07579195 2026-05-14
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
University of Washington
Phase 1/2 Not yet recruiting
NCT07214298 2026-04-30
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1/2 Recruiting
NCT06483555 2026-04-23
PANGEA
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07456852 2026-03-09
Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT04380545 2026-03-06
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT04689347 2026-01-12
5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 1/2 Recruiting
NCT05627635 2025-11-10
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT01489865 2025-11-06
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Georgetown University
Phase 1/2 Completed
NCT04821284 2025-11-04
Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer
Thomas Jefferson University
Phase 1/2 Active not recruiting
NCT07204574 2025-10-02
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Chang Gung Memorial Hospital
Phase 1/2 Recruiting
NCT06531434 2025-09-22
Establishing Best Treatment Strategy for T4 Esophageal Cancer
National Cheng-Kung University Hospital
Phase 1/2 Recruiting
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT06741020 2025-05-23
HAICI
Zhejiang Cancer Hospital
Phase 1/2 Recruiting
NCT03699319 2025-01-23
CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT06782685 2025-01-20
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT06712381 2024-12-02
Carac & PDT Combination in the Treatment Of Actinic Keratoses
Skin Laser & Surgery Specialists
Phase 1/2 Completed
NCT03337087 2024-05-17
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT06409637 2024-05-10
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Not yet recruiting
NCT06370754 2024-04-17
FD-IMPACT
Fudan University
Phase 1/2 Not yet recruiting
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT06259058 2024-03-15
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Not yet recruiting
NCT04324307 2023-09-01
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
Changhai Hospital
Phase 1/2 Unknown
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT05251038 2023-05-11
Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT03294252 2022-04-25
PIPOX
Institut Cancerologie de l'Ouest
Phase 1/2 Terminated
NCT00932438 2021-06-11
DEBIRI
University of Louisville
Phase 1/2 Completed
NCT01217060 2021-04-13
Trimodality Management of T1b Esophageal Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01302613 2020-08-20
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
University of Texas Southwestern Medical Center
Phase 1/2 Withdrawn
NCT00003086 2020-07-14
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
Louisiana State University Health Sciences Center Shreveport
Phase 1/2 Terminated
NCT03606928 2020-03-20
mFLOT Chemotherapy as First-line Treatment in GC
Ruijin Hospital
Phase 1/2 Completed
NCT01671488 2020-02-17
276
Brown University
Phase 1/2 Terminated
NCT01206530 2019-04-18
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT00711243 2019-02-26
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Northwestern University
Phase 1/2 Completed
NCT00052429 2018-01-09
High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03307941 2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2 Withdrawn
NCT00463840 2017-12-05
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
NYU Langone Health
Phase 1/2 Terminated
NCT00188266 2017-09-20
Study of Adjuvant Radiochemotherapy for Gastric Cancer
University Health Network, Toronto
Phase 1/2 Completed
NCT01716949 2017-08-11
HyRec
University of Erlangen-Nürnberg Medical School
Phase 1/2 Unknown
NCT01231399 2017-05-31
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT00307736 2017-05-10
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT00948688 2017-05-10
Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
Massachusetts General Hospital
Phase 1/2 Terminated
NCT01047293 2017-04-04
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
University of Utah
Phase 1/2 Completed
NCT00003582 2016-12-15
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
University of Miami
Phase 1/2 Completed
NCT01611857 2016-11-23
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00526110 2016-10-31
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01488552 2016-08-18
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Pancreatic Cancer Research Team
Phase 1/2 Completed
NCT01473303 2016-06-28
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT00544362 2016-05-30
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Phase 1/2 Completed